Chemistry:Nepadutant
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Routes of administration | Injection[1][2] |
| ATC code |
|
| Pharmacokinetic data | |
| Bioavailability | <3% (oral)[1] |
| Elimination half-life | 44 minutes (IV)[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C45H60N10O14 |
| Molar mass | 965.031 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Nepadutant (INN) (code name MEN-11420) is a glycosylated bicyclic cyclohexapeptide drug which acts as a highly selective NK2 receptor antagonist.[2][3][4] It was developed by the Menarini Group and investigated for the treatment of functional gastrointestinal disorders and asthma but was never marketed.[3][5][6]
See also
- GR-159,897
- Ibodutant
- Saredutant
References
- ↑ 1.0 1.1 1.2 Annual Reports in Medicinal Chemistry. Academic Press. 8 September 1999. pp. 56–. ISBN 978-0-08-058378-5. https://books.google.com/books?id=pJ1TIGO9VVYC&pg=PA56.
- ↑ 2.0 2.1 Tachykinins. Springer. 17 June 2004. pp. 224–226. ISBN 978-3-540-20690-3. https://books.google.com/books?id=Fo4bKOwXbgsC&pg=PA224.
- ↑ 3.0 3.1 Sex and Gender Differences in Pharmacology. Springer Science & Business Media. 2 October 2012. pp. 489–. ISBN 978-3-642-30726-3. https://books.google.com/books?id=-r02bdyoSEgC&pg=PA489.
- ↑ Royal Society of Chemistry (Great Britain) (January 2003). Amino Acids, Peptides and Proteins. Royal Society of Chemistry. ISBN 978-0-85404-242-5. https://books.google.com/books?id=WcMdAQAAMAAJ.
- ↑ Women's Issues in Gastroenterology, An Issue of Gastroenterology Clinics. Elsevier Health Sciences. 29 June 2011. pp. 54–55. ISBN 978-1-4557-1220-5. https://books.google.com/books?id=1naXWRfNZIMC&pg=PT54.
- ↑ Neurogenic Inflammation in Health and Disease. Elsevier. 27 November 2008. pp. 297–. ISBN 978-0-444-53229-9. https://books.google.com/books?id=yvsEGxG5gNcC&pg=PA297.
 |  |
